EGFR and non-small cell lung carcinoma: The approved small-tyrosine kinase inhibitors (TKIs) of EGFR, gefitinib (IressaTM), erlotinib (TarcevaTM), and afatinib (tykerbTM), are effective in a group of NSCLC patients whose tumors carry stimulating mutations within the kinase domain of EGFR (16–19).